Advanced in Peripheral T-Cell Lymphoma

Jung Y. Hong

Seoul, KR 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Peripheral T-Cell Lymphoma
Seoul, KR 
OverviewLocationsClinical Research

Overview

Jung Hong practices in Seoul, Republic of Korea. Hong is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy.

Their clinical research consists of co-authoring 202 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Peripheral T-Cell Lymphoma.

Locations

Seoul, Republic of Korea
Other Locations
Daejeon, Republic of Korea
Sejong, Republic of Korea
Ansan, Republic of Korea
Gangneung, Republic of Korea
Gyeonggi-do, Republic of Korea
Republic of Korea
Cheongju-si, Republic of Korea
Wondu, Republic of Korea
Seoul St. Mary's Hospital, #505 Banpo Dong, Seocho, 137701, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2

202 Total Publications

Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy.
Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: September 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hong's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile